The NEUROG2 antibody is a crucial tool in neuroscience research, targeting the transcription factor Neurogenin 2 (NEUROG2), a key regulator of neuronal differentiation and development. NEUROG2 belongs to the basic helix-loop-helix (bHLH) family of proteins and plays a central role in specifying neuronal fate during embryogenesis, particularly in the central nervous system and retina. It drives progenitor cells toward glutamatergic neuron lineages while suppressing alternative cell fates. Researchers use NEUROG2 antibodies to study its expression patterns, subcellular localization, and interactions with co-factors like E47 or EBF2. These antibodies are widely applied in techniques such as immunohistochemistry, Western blotting, and immunofluorescence to investigate neurodevelopmental processes, stem cell differentiation, and disease mechanisms. In disease contexts, altered NEUROG2 expression has been implicated in neurodevelopmental disorders, brain tumors, and neurodegenerative conditions. The antibody’s specificity is often validated through knockout controls or siRNA knockdown, with many commercial versions targeting conserved epitopes in the bHLH domain. Recent applications extend to reprogramming studies, where NEUROG2 overexpression combined with other factors can convert non-neuronal cells into functional neurons. Proper validation remains critical, as off-target reactivity with related bHLH proteins (e.g., NEUROG1/3) could lead to misinterpretation of results.